| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Praxis Precision Medicines prices $525M public offering | 12 | Seeking Alpha | ||
| Fr | Praxis Precision Medicines platziert Kapitalerhöhung über 525 Mio. US-Dollar | 5 | Investing.com Deutsch | ||
| Fr | Praxis Precision Medicines prices $525 million public offering | 1 | Investing.com | ||
| Fr | Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| Do | Praxis Precision Medicines announces proposed public offering | 11 | Seeking Alpha | ||
| Do | Praxis Precision Medicines, Inc. Announces Proposed Public Offering | 4 | GlobeNewswire (USA) | ||
| Do | Praxis Precision surges, analysts see 'blockbuster potential' for ulixacaltamide | 1 | Investing.com | ||
| Do | Studienerfolg bei Tremor-Medikament: Aktie von Praxis Precision Medicines explodiert, Oppenheimer verdoppelt Kursziel | 14 | Investing.com Deutsch | ||
| PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
| Do | Praxis Precision Medicines stock soars as Oppenheimer raises price target on trial success | 2 | Investing.com | ||
| Do | Truist Securities raises Praxis Precision Medicines stock price target to $360 on positive trial results | 2 | Investing.com | ||
| Do | Baird raises Praxis Precision Medicines stock price target to $275 on positive trial results | 1 | Investing.com | ||
| Do | Praxis Precision Medicines stock price target raised to $251 by TD Cowen | 3 | Investing.com | ||
| Do | Baird hebt Kursziel für Praxis Precision Medicines nach Studienerfolg auf 275 US-Dollar an | 2 | Investing.com Deutsch | ||
| Do | Praxis Precision Medicines: Truist Securities vervierfacht Kursziel nach Studienerfolg auf 360 US-Dollar | 4 | Investing.com Deutsch | ||
| Do | Praxis Precision Medicines: TD Cowen erhöht Kursziel auf 251 US-Dollar | 1 | Investing.com Deutsch | ||
| Do | The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% | 1 | Investor's Business Daily | ||
| Do | Praxis Precision Medicines: Guggenheim erhöht Kursziel nach Studienerfolg auf 350 $ | 2 | Investing.com Deutsch | ||
| Do | Guggenheim raises Praxis Precision Medicines stock price target to $350 on positive trial data | 1 | Investing.com | ||
| Do | Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday | 4 | Benzinga.com | ||
| Do | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,740 | -1,20 % | Aixtron, Evotec, Hensoldt, Puma, Ströer, Suss MicroTec - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| QIAGEN | 42,035 | -0,17 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| MODERNA | 23,090 | -2,51 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
| AMGEN | 260,80 | +0,48 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| NOVAVAX | 7,220 | -2,45 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 127,50 | +1,15 % | Biogen Inc.: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality... ► Artikel lesen | |
| ILLUMINA | 83,77 | -1,82 % | Roche fordert Illumina mit neuer Gen-Sequenzierung-Technologie heraus | DJ Roche fordert Illumina mit neuer Gen-Sequenzierung-Technologie heraus
Von Bill Alpert
DOW JONES--Das Gen-Sequenzierungslabor des Broad Institute hat in dieser Woche das DNA-Genom von Säuglingen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 57,50 | -8,00 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
| INOVIO PHARMACEUTICALS | 2,000 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,317 | -2,37 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 21,500 | -7,53 % | Intellia (NTLA) Soars 13% to Fresh High | ||
| COSCIENS BIOPHARMA | 2,160 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| EDITAS MEDICINE | 3,091 | -7,46 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,952 | -1,16 % | BioCryst's $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE | ||
| SAREPTA THERAPEUTICS | 19,400 | -3,58 % | Sarepta-Aktie: Zurück zu altem Glanz? | Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten... ► Artikel lesen |